Health policy and clinical operations
What the Medicaid and ACA Debate Means for Oncology Trial Access
What the Medicaid and ACA subsidy debate could mean for oncology trial access, and how sites can handle coverage changes before a visit is missed.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
An oncology trial participant can have a scan scheduled and still face a delay if their health coverage changes. The post-election debate over Medicaid and Affordable Care Act (ACA) Marketplace subsidies matters to cancer research because insurance can help pay for routine care before and during a trial. The practical question for sites is whether they can resolve a coverage issue before it disrupts a referral, treatment visit or endpoint assessment.
What Congress is considering and what current law requires
Following the November midterms, House Democratic leader Hakeem Jeffries called for reversing Medicaid cuts and restoring enhanced ACA premium tax credits in the first 100 days of the new Congress. The enhanced credits expired at the end of 2025. Restoring them or reversing Medicaid provisions would require new legislation. [1–3]
Under current law, federal Medicaid work or other qualifying activity requirements for certain adults are due to begin January 1, 2027, and states can implement them sooner. A separate provision requires six-month eligibility renewals for certain expansion adults for renewals scheduled on or after January 1, 2027. Application and exceptions depend on the provision and the individual’s circumstances. [4, 5]
KFF’s analysis of federal data found that 19.2 million people had active Marketplace coverage in February 2026, down from 21.8 million in February 2025. Those counts describe insurance enrollment. The effect on any oncology study will depend on which communities its sites serve and what care those patients need. [3]
What Medicaid covers in a qualifying clinical trial
Federal law requires Medicaid to cover routine patient costs for enrollees in qualifying clinical trials. That can include care for complications that the state plan would otherwise cover and services needed to administer the investigational intervention. The statute excludes the investigational item itself and services solely for research data collection when those items or services would otherwise fall outside the state plan or waiver. Research billing should confirm the planned payer for each service through the site’s coverage analysis and study budget. [6, 7]
Coverage is relevant to who shows up in the evidence. A 2023 JAMA Oncology study examined 51,751 participants in the SWOG Cancer Research Network enrolled from 1992 to 2020. Medicaid expansion under the ACA was associated with greater use of Medicaid among enrolled participants. The study describes insurance use in those trials. The effects of the 2027 rules on who is referred, enrolls or completes visits remain open questions. [8]
What this means for trial teams
Before activation, rehearse a coverage change. Consider a hypothetical patient whose insurance changes before a scheduled scan. The coordinator flags the assessment window. Research billing checks the scan against the coverage analysis and confirms the payer pathway. A financial navigator helps the participant work through coverage and cost questions. If the assessment is at risk, the investigator determines the clinical response and the site follows the protocol’s escalation pathway.
Track barriers before consent and after enrollment. Capture the stage, cause, time to resolution and visit impact in the appropriate site records. Where authorized, share aggregate trends with the sponsor. A rise in unbooked visits attributed to payer verification calls for a different response from an imaging-capacity problem. Travel and lodging can create separate barriers, so confirm what the approved study reimbursement process covers. [9, 10]
Give the monitor a finding they can verify. Using Lampgen’s SIGNAL™ framework, a CRA can verify the documented timeline and escalate through the monitoring plan. The study manager can look for the same delay across sites, assign an owner and check whether similar assessments get booked within the window after the fix. Lampgen Clinical Research staffs oncology CRAs for work that requires this kind of judgment. [12]
Sources
- STAT, Daniel Payne on the post-election health care agenda, November 9, 2026
- Office of House Democratic Leader Hakeem Jeffries, first-100-days priorities
- KFF, 2026 ACA Marketplace enrollment and premium trends
- CMS, Medicaid community engagement implementation
- CMS, State Medicaid Director Letter 26-001 on eligibility redeterminations
- CMS, mandatory Medicaid coverage of routine costs in qualifying clinical trials
- U.S. Code, 42 U.S.C. § 1396d(gg), definitions of routine costs and qualifying trials
- Unger et al., Medicaid expansion and participation in cancer clinical trials, JAMA Oncology, 2023
- FDA, payment and reimbursement to research subjects
- Lampgen Clinical Insights, trial participation burden and patient access
- Lampgen Clinical Insights, how the new Congress could affect NIH funding
- Lampgen Clinical Research, oncology CRA staffing